Indivior Pharmaceuticals (INDV) CAO purchases 1,500 common shares

Rhea-AI Filing Summary

Indivior Pharmaceuticals, Inc. reports that Chief Accounting Officer Anderson Woodrow D purchased 1,500 shares of common stock on 2026-08-05 at $36.28 per share in an open-market or private transaction. Following this buy, he directly owns 26,138 shares of the company’s common stock.

Insider Trade Summary

Net Buyer: 1,500 shares

Net Buy 1 txn

Insider Anderson Woodrow D

Role Chief Accounting Officer

Bought 1,500 shs ($54K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	1,500	$36.28	$54K

Holdings After Transaction: Common Stock — 26,138 shares (Direct)

Key Figures

Shares purchased: 1500.0000 shares Price per share: $36.2800 Shares owned after transaction: 26138.0000 shares +1 more

4 metrics

Shares purchased 1500.0000 shares Common Stock transaction on 2026-08-05

Price per share $36.2800 Purchase in open market or private transaction

Shares owned after transaction 26138.0000 shares Directly held Common Stock following the reported purchase

Transaction date 2026-08-05 Date of reported purchase of Common Stock

Key Terms

non-derivative, direct ownership, transaction code P

3 terms

non-derivative financial

"The security is reported as a non-derivative Common Stock holding."

direct ownership financial

"Ownership type is classified as direct ownership (code D)."

transaction code P regulatory

"Transaction code P indicates a purchase in open market or private transaction."

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/05/2026 - 04:53 PM Accepted by SEC EDGAR 08/05/2026 - 04:52 PM Learn about SEC filing dates

FAQ

What insider transaction did Indivior (INDV) recently report?

Indivior reported that Chief Accounting Officer Anderson Woodrow D purchased 1,500 shares of its common stock on 2026-08-05 at $36.28 per share, increasing his direct ownership to 26,138 shares.

Who was the insider involved in the latest Indivior (INDV) Form 4 filing?

The insider is Anderson Woodrow D, Chief Accounting Officer of Indivior Pharmaceuticals, Inc. He reported buying 1,500 shares of common stock at $36.28 per share, bringing his direct holdings to 26,138 shares.

How many Indivior (INDV) shares does the CAO own after this transaction?

After the reported transaction, Chief Accounting Officer Anderson Woodrow D directly owns 26,138 shares of Indivior common stock. This reflects his purchase of 1,500 shares on 2026-08-05 in an open-market or private transaction.

Was the Indivior (INDV) insider transaction a purchase or a sale?

The reported insider transaction was a purchase. Chief Accounting Officer Anderson Woodrow D bought 1,500 shares of Indivior common stock at $36.28 per share on 2026-08-05, increasing his direct holdings.

At what price did the Indivior (INDV) CAO acquire shares in the Form 4 filing?

Chief Accounting Officer Anderson Woodrow D acquired 1,500 shares of Indivior common stock at a price of $36.28 per share. The transaction date was 2026-08-05, and his direct ownership rose to 26,138 shares afterward.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Anderson Woodrow D

(Last) (First) (Middle)

10710 MIDLOTHIAN TURNPIKE

SUITE 125

(Street)

NORTH CHESTERFIELD VIRGINIA 23235

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Indivior Pharmaceuticals, Inc. [ INDV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Accounting Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/05/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/05/2026		P		1,500	A	$36.28	26,138	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

	/s/Alice Givens, Power of Attorney	08/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)